Trials in healthy subjects

 

Report Year

Trial Code

Trial Title

Clinicaltrials.gov

EudraCTno.

Source

2017

LP0058-1267

LEO 32731 - A Phase I Drug-Drug Interaction Study With LEO 32731 and Midazolam in Healthy Male Subjects

NCT02753218

2015-005073-20

Summary

Active Substance

LEO 32731

LEO Pharma Product

N/A

Formulation

tablet

Trial Phase

1

Population

adults

2017

LP0053-1276

Vasoconstriction Trial Comparing LEO 90100 With Dermovate Cream, Diprosone Ointment, Elocon Cream, Locoid Ointment and LEO 90100 Vehicle

NCT02973776

N/A

Summary

Report

Active Substance

calcipotriol + betamethasone dipropionate

LEO Pharma Product

Enstilar®

Formulation

foam

Trial Phase

1

Population

adults

2017

LP0076-1081

Dermatopharmacokinetic Trial of LEO 80185 Gel

NCT02605057

N/A

Summary

Active Substance

calcipotriol + betamethasone dipropionate

LEO Pharma Product

Daivobet®*

Formulation

Gel & ointment

Trial Phase

1

Population

adults

2017

EXP-1187

An Exploratory Psoriasis Plaque Test Trial Investigating the Neurogenic Component in Psoriasis Vulgaris by Use of Botulinum Toxin A as Tool Compound

NCT02973776

N/A

Summary

Report

Active Substance

Botulinum toxin A

LEO Pharma Product

N/A

Formulation

Powder for injection

Trial Phase

1

Population

adults

2017

LP0084-1230

A randomized, controlled study to evaluate the sensitizing potential of LEO 43204 gel and gel vehicle in healthy volunteers using a repeat insult patch test design

NCT02650505

N/A

Summary

Active Substance

ingenol disoxate

LEO Pharma Product

N/A

Formulation

gel

Trial Phase

1

Population

adults

2016

LP0058-1114

LEO 32731 - A Phase I, single-blind, placebo-controlled, single and multiple oral dose, safety, tolerability and pharmacokinetic study in healthy subjects

NCT02514694

2014-003337-25

Summary

Active Substance

LEO 32731

LEO Pharma Product

N/A

Formulation

tablet & capsule

Trial Phase

1

Population

adults

2016

LP0076-1080

Skin irritation test of LEO 80185 gel (calcipotriol hydrate plus betamethasone dipropionate) in healthy Japanese subjects

NCT02379793

N/A

Summary

Report

 

Active Substance

calcipotriol + betamethasone dipropionate

LEO Pharma Product

Daivobet®

Formulation

gel

Trial Phase

1

Population

adults

2015

EXP-1090

A single-centre, explorative, randomised, investigator-blinded, negative-controlled, phase I clinical trial with intra-individual comparison of treatments to assess steroid induced skin atrophy on healthy skin

NCT02355639

2014-001450-42

Summary

Active Substance

N/A

LEO Pharma Product

N/A

Formulation

ointment

Trial Phase

1

Population

adults

2015

LP0058-1005

LP0058-1005 - A phase 1, open-label, four-way crossover and food-effect study of LEO 32731 in healthy subjects when administered as an immediate and modified release formulation

NCT02126371

2013-004346-41

Summary

Active Substance

LEO 32731

LEO Pharma Product

N/A

Formulation

tablet & capsule

Trial Phase

1

Population

adults

2015

SKAT-1129

A single-centre, prospective, randomised, investigator-blinded, vehicle-controlled, phase I clinical trial with intra-individual comparison of treatments to assess the potential of LEO 130852A gel to reduce steroid induced skin atrophy on healthy skin

NCT02392130

2014-003677

Summary

Active Substance

N/A

LEO Pharma Product

N/A

Formulation

ointment

Trial Phase

1

Population

adults

2014

LP0053-66

Combined cumulative irritation potential and repeat insult patch test of LEO 90100 areosol foam

NCT01935869

2012-004264-21

Summary

Report

Active Substance

calcipotriol + betamethasone dipropionate

LEO Pharma Product

Enstilar®

Formulation

foam

Trial Phase

1

Population

adults

2014

LP0053-69

A vasoconstriction study with LEO 90100

NCT01946386

2012-002660-28

Summary

Report

Active Substance

calcipotriol + betamethasone dipropionate

LEO Pharma Product

Enstilar® & Daivobet®

Formulation

foam & ointment

Trial Phase

1

Population

adults

2011

LP0041-01

PEP005 gel – evaluation of local tolerability after exposure to ingenol mebutate 0.05% and 0.015% gel followed by hand washing in healthy subjects

NCT01302925

N/A

Summary

Report

Active Substance

ingenol mebutate

LEO Pharma Product

Picato®

Formulation

gel

Trial Phase

1

Population

Adults

2011

MCB 0902

Multiple dose study of LEO 90105 – calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate)

NCT01293383

2014-003677

Summary

Report

Active Substance

calcipotriol + betamethasone dipropionate

LEO Pharma Product

Daivobet®

Formulation

ointment

Trial Phase

1

Population

adults

2011

MCB 0901

Skin irritation test of LEO 90105 – calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate)

NCT01293357

N/A

Summary

Report

Active Substance

calcipotriol + betamethasone diprop. & calcipotriol

LEO Pharma Product

Daivobet® & Daivonex®/ Dovonex®

Formulation

ointment

Trial Phase

1

Population

adults

2010

MCO 0901 FR

An irritation study with new calcipotriol ointment formulations in healthy subjects

NCT01105234

2009-017394-38

Summary

Report

Active Substance

calcipotriol

LEO Pharma Product

Daivonex®/ Dovonex®

Formulation

cream

Trial Phase

1

Population

adults

2009

PEP005-024

A randomized, controlled study to evaluate the photoallergic potential of PEP005 (ingenol mebutate) gel, 0.01% in healthy volunteers using an open application photoallergic test design

NCT00850681

N/A

Summary

Report

Active Substance

ingenol mebutate

LEO Pharma Product

N/A

Formulation

gel

Trial Phase

1

Population

adults

2009

PEP005-023

A randomized, controlled study to evaluate the sensitizing ootential of PEP005 topical gel (0.01% concentration) in healthy volunteers using a repeat insult patch test design

NCT00850811

N/A

Summary

Report

Active Substance

ingenol mebutate

LEO Pharma Product

N/A

Formulation

gel

Trial Phase

1

Population

adults

2008

CE 0701 DK

Single dose bioequivalence study of Centyl® K, LEO new tablet formulation vs. existing formulation of Centyl® K in healthy subjects of either sex

N/A

2007-005987-29

Summary

Report

Active Substance

bendroflumethiazide + potassium chloride

LEO Pharma Product

Centryl® K & Centryl® K Mite

Formulation

tablet

Trial Phase

1

Population

adults

2007

MBL 0501 FR

In vivo bioequivalence study of betamethasone dipropionate in Daivobet/Dovobet gel and Diprosone lotion according to FDA guideline for vasoconstrictor bioassay

N/A

N/A

Summary

Report

Active Substance

calcipotriol + betamethasone dipropionate

LEO Pharma Product

Daivobet®

Formulation

gel

Trial Phase

1

Population

adults

2007

MBL 0601 FR

Assessment of the atrophogenic potential and dermal tolerance of Daivobet/Dovobet gel compared with Diprosone® ointment

N/A

N/A

Summary

Report

Active Substance

calcipotriol + betamethasone dipropionate

LEO Pharma Product

Daivobet®

Formulation

gel

Trial Phase

1

Population

adults

2007

MBL 0403 FR

In vivo bioequivalence study of betamethasone dipropionate in Daivobet/Dovobet gel and Diprosone ointment according to FDA guideline for vasoconstrictor bioassay

N/A

2004-000036-84

Summary

Report

Active Substance

calcipotriol + betamethasone dipropionate

LEO Pharma Product

Daivobet®

Formulation

gel

Trial Phase

1

Population

adults

2007

OA 0402 DE

A phase I pharmacokinetic study with repeated doses of alfacalcidol in patients with chronic renal failure undergoing haemodialysis

N/A

2004-004379-12

Summary

Report

Active Substance

calcipotriol + betamethasone dipropionate

LEO Pharma Product

One-Alpha®

Formulation

capsule

Trial Phase

1

Population

adults

2006

MBL 0402 UK

Assessment of the atrophogenic potential and dermal tolerance of Daivobet/Dovobet gel compared with Diprosone® ointment

N/A

2005-001 225-29

Summary

Report

Active Substance

calcipotriol + betamethasone dipropionate

LEO Pharma Product

Daivobet®

Formulation

gel

Trial Phase

1

Population

adults

2006

PEP005-005

A randomized, controlled study to evaluate the sensitizing ootential of PEP005 topical gel (0.01% concentration) in healthy volunteers using a repeat insult patch test design

NCT00357916

N/A

Summary

Report

Active Substance

ingenol mebutate

LEO Pharma Product

gel

Formulation

gel

Trial Phase

1

Population

adults

2006

MBL 0302 FR

Repeat insult patch test with Daivobet/Dovobet gel including 21-days cumulative irritation study and sensitisation potential in 200 healthy subjects

N/A

N/A

Summary

Report

Active Substance

calcipotriol + betamethasone dipropionate

LEO Pharma Product

Daivobet®

Formulation

gel

Trial Phase

1

Population

adults

2006

MBL 0301 UK

Assessment of the photosensitisation potential of Daivobet/Dovobet gel containing calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)

N/A

2005-001226-91

Summary

Report

Active Substance

calcipotriol + betamethasone dipropionate

LEO Pharma Product

Daivobet®

Formulation

gel

Trial Phase

1

Population

adults

2006

OA 0401 CA

A bioavailability study to assess the bioequivalence of alfacalcidol capsule and oral drop formulations: A comparative, randomized, single-dose, 4-way crossover bioavailability study of LEO Pharma A/S alfacalcidol (One-Alpha®) capsules and oral drops following a dose of 10 µg in healthy adult volunteers under fasting conditions

N/A

N/A

Summary

Report

Active Substance

alfacalcidol

LEO Pharma Product

One-Alpha®

Formulation

capsule & oral drops

Trial Phase

1

Population

adults

2005

MBL 0303 FR

Phototoxicity study: Assessment of the phototoxic potential of Daivobet/Dovobet (calcipotriol 50mcg/g plus betamethasone 0.5 mg/g (as dipropionate)) gel

N/A

N/A

Summary

Report

Active Substance

calcipotriol + betamethasone dipropionate

LEO Pharma Product

Daivobet®

Formulation

gel

Trial Phase

1

Population

adults

2005

OA 0403 CA

A bioavailability study to investigate food interaction with a single dose of alfacalcidol: A comparative, randomized, single-dose, 3-way crossover, food effect and absolute bioavailability study of LEO Pharma alfacalcidol (One-Alpha®) following a dose of 10 μg in healthy adult volunteers

N/A

N/A

Summary

Report

Active Substance

alfacalcidol

LEO Pharma Product

One-Alpha®

Formulation

capsule & injectional solution

Trial Phase

1

Population

adults

2004

MCB 0306 UK

Daivobet/Dovobet ointment / UV penetration study in humans - detection of erythema induced by UV light, a within subject comparison of investigational materials against untreated skin

N/A

N/A

Summary

Report

Active Substance

calcipotriol + betamethasone diprop. &calcipotriol

LEO Pharma Product

Daivobet® & Daivonex®/ Dovonex®

Formulation

ointment & scalp solution

Trial Phase

1

Population

adults

2003

MCB 0202 FR

Repeat insult patch test with Daivobet / Dovobet ointment - a study on the sensitisation potential of Daivobet / Dovobet ointment and the ointment vehicle when applied on healthy skin in 200 healthy subjects

N/A

N/A

Summary

Report

Active Substance

calcipotriol + betamethasone dipropionate

LEO Pharma Product

Daivobet®

Formulation

ointment

Trial Phase

1

Population

adults

2003

MCB 0204 FR

Photo-allergy test: Assessment of the photosensitisation potential of Daivobet/Dovobet ointment (calcipotriol 50 µg/g and betamethasone (as dipropionate) 0.5 mg/g)

N/A

N/A

Summary

Report

Active Substance

calcipotriol + betamethasone dipropionate

LEO Pharma Product

Daivobet®

Formulation

ointment

Trial Phase

1

Population

adults

2003

MCB 0203 FR

21-day cumulative irritation test: Assessment of the local skin tolerability, after repeated application of Daivobet/Dovobet ointment (calcipotriol 50 µg/g and betamethasone (as dipropionate) 0.5 mg/g)

N/A

N/A

Summary

Report

Active Substance

calcipotriol + betamethasone dipropionate

LEO Pharma Product

Daivobet®

Formulation

ointment

Trial Phase

1

Population

adults

2002

MCB 0101 FR

Photo-toxicity study: Assessment of the phototoxic potential of Daivobet®/Dovobet® ointment (betamethasone dipropionate 0.5mg/g and calcipotriol 50μg/g)

N/A

N/A

Summary

Report

Active Substance

calcipotriol + betamethasone dipropionate

LEO Pharma Product

Daivobet®

Formulation

ointment

Trial Phase

1

Population

adults

2001

MCO 9407 CA

Atrophogenic potential of calcipotriol, betamethasone and mometasone

N/A

N/A

Summary

Report

Active Substance

calcipotriol

LEO Pharma Product

Daivonex®/ Dovonex®

Formulation

ointment

Trial Phase

1

Population

adults

2000

IN 9801 FR

An open (uncontrolled) clinical phase I study to assess the pharmacokinetic profile of tinzaparin (innohep®, LEO) after multiple subcutaneous doses in healthy male volunteers

N/A

N/A

Summary

Report

Active Substance

tinzaparin

LEO Pharma Product

innohep®

Formulation

injectional solution

Trial Phase

1

Population

adults

1999

MET 9802 FR

A comparative single dose bioavailability study of mecillinam in eighteen healthy male volunteers following oral administration of a new 400 mg pivmecillinam tablet versus oral administration of two 200 mg pivmecillinam tablets.

N/A

N/A

Summary

Report

Active Substance

pivmecillinam

LEO Pharma Product

Selexid®

Formulation

tablet

Trial Phase

1

Population

adults

1998

BUN 9403 DE

Bioavailability of 2 mg formulations for nasal and rectal administration of bumetanide

N/A

N/A

Summary

Report

Active Substance

bumetanide

LEO Pharma Product

Burinex®

Formulation

spray, suppositorie, tablet & injectional solution

Trial Phase

1

Population

adults

1998

FUT 9407 FR

Diffusion of fusidic acid, oxacillin and pristinamycin in interstitial dermal liquid

N/A

N/A

Summary

Report

Active Substance

sodium fusidate

LEO Pharma Product

Fucidin®

Formulation

tablet

Trial Phase

1

Population

adults

1998

MCO 9701 NL

Calcipotriol ointment and cream and the minimal erythema dose

N/A

N/A

Summary

Report

Active Substance

calcipotriol

LEO Pharma Product

Daivonex®/ Dovonex®

Formulation

ointment & cream

Trial Phase

1

Population

adults

1998

MCW 9702 UK

(3H)-MC 903 (calcipotriol scalp solution II): A study of percutaneous absorption and excretion following topical administration to healthy male volunteers

N/A

N/A

Summary

Report

Active Substance

calcipotriol

LEO Pharma Product

Daivonex®/ Dovonex®

Formulation

scalp solution

Trial Phase

1

Population

adults

1997

FUS 9602 UK

Evaluation of the bioavailability of a new oral suspension of fusidic acid versus a dry granulated, film coated tablet of sodium fusidate in healthy volunteers.”)

N/A

N/A

Summary

Report

Active Substance

fusidic acid & sodium fusidate

LEO Pharma Product

Fucidin®

Formulation

oral suspension & tablet

Trial Phase

1

Population

adults

1996

FU 192 CA / FPC191

Evaluation of the pharmacokinetics of fusidic acid in healthy volunteers

N/A

N/A

Summary

Report

Active Substance

sodium fusidate

LEO Pharma Product

Fucidin®

Formulation

tablet

Trial Phase

1

Population

adults

1996

FU 192

Evaluation of the bioavailability of wet granulated film coated and a dry granulated, film coated tablet of sodium fusidate in healthy volunteers

N/A

N/A

Summary

Report

Active Substance

sodium fusidate

LEO Pharma Product

Fucidin®

Formulation

tablet

Trial Phase

1

Population

adults

1995

BUT 9401 NL

Evaluation of the bioavailability of a 0.5 mg tablet of bumetanide in healthy volunteers

N/A

N/A

Summary

Report

Active Substance

bumetanide

LEO Pharma Product

Burinex®

Formulation

tablet

Trial Phase

1

Population

adults

1994

BU 9302 CA

Evaluation of the bioavailability of a 2 mg tablet of bumetanide in healthy volunteers

N/A

N/A

Summary

Report

Active Substance

bumetanide

LEO Pharma Product

Burinex®

Formulation

tablet

Trial Phase

1

Population

adults

1993

BU 9301 F

Absolute bioavailability of bumetanide after intramuscular injection: a randomized, open, cross-over study comparing bumetanide (2 mg I 4 ml) administered by I.V. or I.M. route in normal healthy

N/A

N/A

Summary

Report

Active Substance

bumetanide

LEO Pharma Product

Burinex®

Formulation

injectional solution

Trial Phase

1

Population

adults

1993

FUC 390 F

Pharmacokinetic study of oral fusidic acid (formulation: film-coated tablet) after the first dose and repeated doses in elderly subjects

N/A

N/A

Summary

Report

Active Substance

sodium fusidate

LEO Pharma Product

Fucidin®

Formulation

tablet

Trial Phase

1

Population

elderly

1992

KM 191 F

Comparison of intragastric dispersion for two solid forms of microencapsulated potassium chloride (tablet and capsule)

N/A

N/A

Summary

Report

Active Substance

sodium fusidate

LEO Pharma Product

N/A

Formulation

tablet & capsule

Trial Phase

1

Population

elderly

1992

KM 190 F

Comparison of intragastric PD variations caused by the administration of potassium chloride

N/A

N/A

Summary

Report

Active Substance

sodium fusidate

LEO Pharma Product

N/A

Formulation

solution, tablet & capsule

Trial Phase

1

Population

adults

1990

BUR 190 NL

A single dose bioequivalence study on bumetanide tablets: 1 x 5 mg Burinex® tablets (Leo Pharmaceutical Products B.V.) compared with 5 x 1 mg Burinex® tablets (Leo Pharmaceutical Products B.V.)

N/A

N/A

Summary

Report

Active Substance

bumetanide

LEO Pharma Product

Burinex®

Formulation

tablet

Trial Phase

1

Population

adults

                 

 

We use cookies on this website

The cookies help us gain a better understanding of how you use our website; display applications and functionalities, to optimise your website experience, to assign a unique identification number to you, and to help you remember your user ID and password when you return to the website. We also use cookies to generate statistical information.

By continuing to browse our website, you are agreeing to our use of cookies

If you want to know more about our cookie policy and how to avoid and delete cookies click here.